Compare BioNano Genomics Inc (BNGO) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $123.16. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | QQQE | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.92 | $122.72 |
52-Week Low | $1.06 | $96.06 |
Enterprise Value | $16.26M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $123.14, up 0.81% with a bullish technical signal from moving averages. The ETF provides equal-weighted exposure to Nasdaq-100 companies, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential inclusion in the index, which could drive additional inflows. Technical indicators show strong momentum with ADX readings above 25, though RSI suggests some overbought conditions near-term.
The equal-weight approach offers defensive positioning against tech concentration risks while maintaining Nasdaq growth exposure. Key catalysts include continued tech sector strength and index rebalancing benefits. Risks involve Nasdaq volatility and potential sector rotation away from growth stocks. The ETF's structure provides diversification benefits for investors seeking balanced Nasdaq exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
